Condition: Melanoma · Clear-Cell Renal-Cell Carcinoma (ccRCC) · Advanced Solid Tumors · Sponsor: Regeneron Pharmaceuticals
This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study drug(s) are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of California San Francisco (UCSF) | San Francisco, California, United States | Recruiting |
| Yale School of Medicine | North Haven, Connecticut, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Start Midwest Cancer Research | Grand Rapids, Michigan, United States | Recruiting |
| Northwell Health | Lake Success, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| University of Pittsburgh Medical Center - Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Next Oncology | San Antonio, Texas, United States | Recruiting |
| The Start Center for Cancer Care | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06413680